Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Superior test-retest reliability of cognitive assessment with Cognivue® vs SLUMS during an 18-month longitudinal study
Aging, Dementia, and Behavioral Neurology
P7 - Poster Session 7 (5:30 PM-6:30 PM)
10-004
Assess the test-retest reliability of the Cognivue cognitive assessment method vs SLUMS during an 18-month longitudinal study.
Cognivue is an FDA-cleared computerized testing tool designed to assess cognitive impairment. In an FDA clearance study, Cognivue demonstrated good agreement with St. Louis University Mental Status (SLUMS) and other neuropsychological tests, and superior test re-test reliability compared to SLUMS across 2 sessions, 1 to 2 weeks apart (Cognivue regression fit: R2= 0.81, r= 0.90); SLUMS regression fit: R2 = 0.67, r= 0.82).
238 subjects from the FDA clearance study enrolled in the longitudinal study. They underwent Cognivue test and SLUMS at 3 sessions over 18 months (6, 12, 18 months post-FDA study). An analysis of rank linear regression test-retest reliability was performed for both tests. In a separate sub-analysis, subjects’ medical records were analyzed to determine the correlation between comorbidities or medication usage and Cognivue score.

Among these 238 patients, Cognivue demonstrated similar linear regression scores across comparisons (test session [TS] 1&2: regression fit: R2= 0.76; r = 0.87; TS 1&3: regression fit: R2= 0.72; r = 0.85; TS 1&4: regression fit: R2= 0.73; r = 0.86). The SLUMS test demonstrated greater variability in regression scores across TS (TS 1&2: regression fit: R2= 0.63; r = 0.79; TS 1&3: regression fit: R2= 0.43 r = 0.65; TS 1&4: regression fit: R2= 0.64; r = 0.80).

Medical records of 203 subjects were analyzed. Overall, an increased co-morbidity count significantly decreased subjects’ Cognivue scores (correlation -0.21; P=0.01).  Cardiopulmonary comorbidities had the largest impact on a patient’s Cognivue score (78.0 score for those without this comorbidity vs 67.1 score for those with; P<0.001).
Cognivue demonstrated superior test re-test reliability compared to SLUMS over 18 months after the FDA clearance study. An increased comorbidity count and cardiopulmonary comorbidities significantly decreased a subject’s Cognivue score over time.
Authors/Disclosures
John C. Andrefsky, MD (University Hospitals Parma)
PRESENTER 		No disclosure on file
No disclosure on file
Reina Benabou, MD, PhD No disclosure on file